The corporate venturing unit of UK-listed pharmaceutical company GlaxoSmithKline has participated in the extension financing raised by US drugs company Constellation Pharmaceuticals.
SR One, the corporate venturing unit of UK-listed pharmaceutical company GlaxoSmithKline, has reinvested in the consortium backing US drugs company Constellation Pharmaceuticals’ $15m series B round extension.
Venture capital firms Third Rock Ventures, The Column Group, Venrock Associates, and Altitude Life Science Ventures also participated in the B extension. Altitude invests on behalf of the Southern Ute Indian Tribe, and counts Steve Johnson, formerly president of corporate venturing unit Tredegar Investments, among its members.
SR One led Constellation’s…
